^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Investigation of APR-246 in Small Cell Lung Cancer

Published date:
02/11/2022
Excerpt:
Interestingly, within our SCLC panel, there is a significant proportion of variant SCLC harboring c-myc amplification that are exquisitely sensitive to APR-246...APR-246 harbors excellent single agent in vitro anti-tumor efficacy across SCLC transcriptional subtypes.